Work

Synthetic DNA immunotherapy in biochemically relapsed prostate cancer

Year: 2018

Type: article

Abstract: Background: INO-5150 (PSA and PSMA) +/- INO-9012 (IL-12), a synthetic DNA immunotherapy, was assessed for safety, immunogenicity and efficacy in biochemically recurrent prostate cancer patients (pts).

Source: Annals of Oncology

DOI: 10.1093/annonc/mdy284.039

Authors: N. Shore, E.I. Heath, L.T. Nordquist, H. Cheng, K. Bhatt, M. Morrow, T. McMullan, K. Kraynyak, J. Lee, B. Sacchetta, L. Liu, S. Rosencranz, S.T. Tagawa, L.J. Appleman, R. Tutrone, J. Garcia, Y. Whang, W. Kelly, I. Csiki, M.L. Bagarazzi

Institutions: Carolina Urologic Research Center, The Barbara Ann Karmanos Cancer Institute, Urology Cancer Center and GU Research Network, University of Washington, Inovio Pharmaceuticals (United States), Weill Cornell Medicine, UPMC Hillman Cancer Center, Chesapeake Urology Associates, Cleveland Clinic, UNC Lineberger Comprehensive Cancer Center, Thomas Jefferson University

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $5,080

OpenAlex ID: W2898454826

FWCI:

Cites:

Cited by:

Related to: 10